-
Something wrong with this record ?
MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in NMYC Amplified Neuroblastoma Cell Lines
B. Feriancikova, T. Feglarova, L. Krskova, T. Eckschlager, A. Vicha, J. Hrabeta
Language English Country Switzerland
Document type Journal Article
Grant support
716218
Grant Agency of Charles University, Prague, Czech Republic
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
33806217
DOI
10.3390/ijms22073393
Knihovny.cz E-resources
- MeSH
- Apoptosis MeSH
- Cell Cycle MeSH
- Glycolysis MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Brain Neoplasms metabolism MeSH
- Neuroblastoma metabolism MeSH
- Cell Movement MeSH
- Cell Proliferation MeSH
- N-Myc Proto-Oncogene Protein metabolism MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- RNA, Long Noncoding genetics metabolism MeSH
- Gene Expression Profiling MeSH
- Gene Silencing MeSH
- Cell Survival MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Neuroblastoma (NBL) is the most common extracranial childhood malignant tumor and represents a major cause of cancer-related deaths in infants. NMYC amplification or overexpression is associated with the malignant behavior of NBL tumors. In the present study, we revealed an association between long non-coding RNA (lncRNA) myocardial infarction associated transcript (MIAT) and NMYC amplification in NBL cell lines and MIAT expression in NBL tissue samples. MIAT silencing induces cell death only in cells with NMYC amplification, but in NBL cells without NMYC amplification it decreases only the proliferation. MIAT downregulation markedly reduces the NMYC expression in NMYC-amplified NBL cell lines and c-Myc expression in NMYC non-amplified NBL cell lines, but the ectopic overexpression or downregulation of NMYC did not affect the expression of MIAT. Moreover, MIAT downregulation results in decreased ornithine decarboxylase 1 (ODC1), a known transcriptional target of MYC oncogenes, and decreases the glycolytic metabolism and respiratory function. These results indicate that MIAT is an upstream regulator of NMYC and that MIAT/NMYC axis disruption induces cell death in NMYC-amplified NBL cell lines. These findings reveal a novel mechanism for the regulation of NMYC in NBL, suggesting that MIAT might be a potential therapeutic target, especially for those with NMYC amplification.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019002
- 003
- CZ-PrNML
- 005
- 20210830100544.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22073393 $2 doi
- 035 __
- $a (PubMed)33806217
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Feriancikova, Barbara $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
- 245 10
- $a MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in NMYC Amplified Neuroblastoma Cell Lines / $c B. Feriancikova, T. Feglarova, L. Krskova, T. Eckschlager, A. Vicha, J. Hrabeta
- 520 9_
- $a Neuroblastoma (NBL) is the most common extracranial childhood malignant tumor and represents a major cause of cancer-related deaths in infants. NMYC amplification or overexpression is associated with the malignant behavior of NBL tumors. In the present study, we revealed an association between long non-coding RNA (lncRNA) myocardial infarction associated transcript (MIAT) and NMYC amplification in NBL cell lines and MIAT expression in NBL tissue samples. MIAT silencing induces cell death only in cells with NMYC amplification, but in NBL cells without NMYC amplification it decreases only the proliferation. MIAT downregulation markedly reduces the NMYC expression in NMYC-amplified NBL cell lines and c-Myc expression in NMYC non-amplified NBL cell lines, but the ectopic overexpression or downregulation of NMYC did not affect the expression of MIAT. Moreover, MIAT downregulation results in decreased ornithine decarboxylase 1 (ODC1), a known transcriptional target of MYC oncogenes, and decreases the glycolytic metabolism and respiratory function. These results indicate that MIAT is an upstream regulator of NMYC and that MIAT/NMYC axis disruption induces cell death in NMYC-amplified NBL cell lines. These findings reveal a novel mechanism for the regulation of NMYC in NBL, suggesting that MIAT might be a potential therapeutic target, especially for those with NMYC amplification.
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a nádory mozku $x metabolismus $7 D001932
- 650 _2
- $a buněčný cyklus $7 D002453
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a pohyb buněk $7 D002465
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a umlčování genů $7 D020868
- 650 _2
- $a glykolýza $7 D006019
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a protoonkogen n-myc $x metabolismus $7 D000071447
- 650 _2
- $a neuroblastom $x metabolismus $7 D009447
- 650 _2
- $a RNA dlouhá nekódující $x genetika $x metabolismus $7 D062085
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Feglarova, Tereza $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
- 700 1_
- $a Krskova, Lenka $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
- 700 1_
- $a Eckschlager, Tomas $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
- 700 1_
- $a Vicha, Ales $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
- 700 1_
- $a Hrabeta, Jan $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 7 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33806217 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100544 $b ABA008
- 999 __
- $a ok $b bmc $g 1689933 $s 1139448
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 7 $e 20210325 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a 716218 $p Grant Agency of Charles University, Prague, Czech Republic
- LZP __
- $a Pubmed-20210728